Elevation Oncology (ELEV) Stock Forecast & Price Target

$0.59

+0.02 (+3.48%)

(As of 09/24/2024 ET)

Elevation Oncology - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 5 Analyst Ratings

Sell
0

Hold
0

Buy
5

Based on 5 Wall Street analysts who have issued ratings for Elevation Oncology in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 5 have given a buy rating for ELEV.

Consensus Price Target

$7.80
1,212.47% Upside

According to the 5 analysts' twelve-month price targets for Elevation Oncology, the average price target is $7.80. The highest price target for ELEV is $10.00, while the lowest price target for ELEV is $6.00. The average price target represents a forecasted upside of 1,212.47% from the current price of $0.59.

Get the Latest News and Ratings for ELEV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Elevation Oncology and its competitors.

ELEV Analyst Ratings Over Time

Type	Current Forecast 9/26/23 to 9/25/24	1 Month Ago 8/27/23 to 8/26/24	3 Months Ago 6/28/23 to 6/27/24	1 Year Ago 9/26/22 to 9/26/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$7.80	$7.80	$7.80	$4.67
Forecasted Upside	1,212.47% Upside	891.99% Upside	210.76% Upside	576.43% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

My grim warning about AI stocks (Ad)

Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.

So go here now to read my new report The Big AI Die-Up… while you still can.

ELEV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ELEV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Elevation Oncology Stock vs. The Competition

Type	Elevation Oncology	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	1,212.47% Upside	915.62% Upside	6.80% Upside
News Sentiment Rating	Neutral News See Recent ELEV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/7/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00	+699.99%
8/6/2024	Wedbush 3 of 5 stars		Reiterated Rating	Outperform	$8.00	+925.37%
7/15/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$7.00 ➝ $7.00	+137.29%
5/31/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Amin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00	+145.70%
5/14/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Loganathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$8.00	+125.99%
5/30/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
5/30/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$5.00 ➝ $8.00	+59.36%
11/10/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:27 AM ET.

ELEV Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Elevation Oncology is $7.80, with a high forecast of $10.00 and a low forecast of $6.00.
: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ELEV shares.
: According to analysts, Elevation Oncology's stock has a predicted upside of 1,212.47% based on their 12-month stock forecasts.
: Elevation Oncology has been rated by research analysts at HC Wainwright, JMP Securities, and Wedbush in the past 90 days.
: Analysts like Elevation Oncology more than other "medical" companies. The consensus rating for Elevation Oncology is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ELEV compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

The most serious warning of my career (Ad)

With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election.

Click here now to grab your seat now.

This page (NASDAQ:ELEV) was last updated on 9/25/2024 by MarketBeat.com Staff

From Our Partners